ロード中...
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer
Tyrosine kinase inhibitors (TKIs) are very effective against non-small cell lung cancer (NSCLC) caused by epidermal growth factor receptor (EGFR) mutation. Before the approval of osimertinib in March 2016, there were only three available EGFR TKIs (gefitinib, erlotinib, and afatinib) for the therapy...
保存先:
| 出版年: | Oncol Res |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Cognizant Communication Corporation
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7844677/ https://ncbi.nlm.nih.gov/pubmed/29321093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/096504018X15151523767752 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|